A2A NEWS

Search

Biomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations in both hematologic and solid cancers, announced the closing of a $56 million Series A financing today. The syndicate is led by Cormorant Asset Management with participation from Boxer Capital of Tavistock Group, Janus Henderson Investors, Rock Springs Capital, RTW Investments, LP, Aisling Capital, Point Sur Investors, Logos Capital and Clifton Capital.


READ MORE

menu
Contact

BioLabs New York
180 Varick Street
New York, NY 10014

​​

Cambridge Innovation Center
1 Broadway 
Cambridge, MA 02142
Boston

Info@Atoms2applications.com

© 2019 A2A Pharma. All rights reserved